All In Biotech

Drug Trial Radar · NCT07931521

Clinical Trial to Evaluate the Safety and Efficacy of DW4421 in Patients With Erosive Reflux Disease

A Randomized, Double-Blind, Active-Controlled, Parallel, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of DW4421 in Patients With Erosive Reflux Disease

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 328 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

328

Actual

Start

Nov 17, 2025

Primary completion

Aug 31, 2026

Study completion Sep 14, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to compare the efficacy and safety of DW4421 to Esomeprazole in patients with Erosive Reflux Disease.

Conditions

  • Erosive Reflux Disease
  • GERD (Gastroesophageal Reflux Disease)

Interventions

  • DW4421 20mgDrug

    DW4421 20mg 1Tab. + DW4421 40mg placebo 1Tab. + Esomeprazole 40mg placebo 1Tab., once daily, PO

  • DW4421 40mgDrug

    DW4421 20mg placebo 1Tab. + DW4421 40mg 1Tab. + Esomeprazole 40mg placebo 1Tab., once daily, PO

  • Esomeprazole 40mgDrug

    DW4421 20mg placebo 1Tab. + DW4421 40mg placebo 1Tab. + Esomeprazole 40mg placebo 1Tab., once daily, PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative healing rate of mucosal break evaluated by BICR (Blind Independent Central Review) at Week 8 after administration of the investigational product (%)Time frame: Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Catholic University of Korea, Incheon, St. Mary's Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.